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Understanding factors associated with varying efficacy of Bacillus Calmette-Guérin (BCG) 22 
would aid the development of improved vaccines against tuberculosis (TB). In addition, 23 
investigation of individual-level factors affecting mycobacterial-specific immune responses 24 
could provide insight into confounders of vaccine efficacy in clinical trials. Mycobacterial 25 
growth inhibition assays (MGIA) have been developed to assess vaccine immunogenicity ex 26 
vivo and provide a measure of  immune function against live mycobacteria. In this study, we 27 
assessed the impact of immune cell phenotype, cytomegalovirus (CMV)-specific response 28 
and sex on ex vivo growth inhibition following historical BCG vaccination in a cohort of 29 
healthy individuals (n=100). A higher frequency of cytokine-producing NK cells in 30 
peripheral blood was associated with enhanced ex vivo mycobacterial growth inhibition 31 
following historical BCG vaccination. A CMV-specific response was associated with T-cell 32 
activation, a risk factor for TB disease and we also observed an association between T-cell 33 
activation and ex vivo mycobacterial growth. Interestingly, BCG-vaccinated f males in our 34 
cohort controlled mycobacterial growth better than males. In summary, our present study has 35 
shown that individual-level factors influence capacity to control mycobacterial growth 36 
following BCG vaccination and the MGIA could be used as a tool to assess how vaccine 37 
candidates may perform in different populations. 38 
 39 






Tuberculosis (TB) is the number one cause of death from an infectious disease worldwide 44 
and it is currently estimated that a quarter of theworld population is infected with 45 
Mycobacterium tuberculosis (Mtb) [1, 2]. The introduction of Bacillus Calmette-Guérin 46 
(BCG) vaccination and chemotherapy in the past century provided optimism to fight the 47 
disease. Despite this, drug-resistant TB is now a major risk to global health security, and 48 
BCG as the only licensed vaccine for TB is known to have a variable efficacy against 49 
contagious adult pulmonary TB [3, 4]. BCG remains as the most widely used vaccine 50 
worldwide, primarily because it provides good protection against TB in children [3]. 51 
Understanding factors associated with varying BCG protection could aid the development of 52 
improved vaccination practice as well as novel vaccines against TB. 53 
It has been proposed that the observed variation in BCG efficacy is attributed to individual-54 
level factors which influence host mycobacteria-specific immune responses [5-7]. In a recent 55 
systematic review, protection following BCG vaccinat on was shown to vary according to the 56 
geographical latitudes in which the vaccine was given. In the UK, a country where exposure 57 
to environmental mycobacteria and/or Mtb is regarded to be lower (latitude > 40o), BCG is 58 
known to provide efficacy of up to 80% against pulmonary TB [8] and vaccination of school-59 
aged children could provide protection for more than 20 years [9]. Another factor that may 60 
influence the mycobacteria-specific immune response is sex. Globally, TB case rates are 61 
much higher in men than in women, as reflected by aglobal male to female ratio (M:F) of 1.7 62 
for case notifications in 2016 [10]. Males contribute to 65% of TB cases worldwide and 63 
although it is thought that socioeconomic and cultura  factors are contributing to the observed 64 
sex bias, differences in the immune responses between the sexes also play a role [11, 12]. It is 65 
generally acknowledged that females exhibit more robust immune responses towards 66 
infection and vaccination compared to males [13]. In the context of susceptibility to TB, 67 
differences in immune cells frequencies and functios have been thought to contribute to 68 
higher TB rates in males [14]. With regard to BCG vaccination, there is currently limited 69 
evidence concerning the impact of sex on its protectiv  effect against pulmonary TB in 70 
adults. Interestingly, BCG is thought to provide a non-specific protective effect against 71 
unrelated pathogens, thus contributing in reduction of overall cause of mortality, and this 72 
effect is more pronounced in females rather than males [15-17]. 73 
 
 4
Recently, Fletcher et al. found that T-cell activation is an immune correlat  of risk of TB 74 
disease in BCG-vaccinated infants in a study enrolli g a large cohort of infants [18]. Chronic 75 
exposure to antigen from persistent viral or bacterial infection is known to drive continuous 76 
T-cell activation which could lead to dysfunction of antigen specific T-cells [19]. Further to 77 
the findings of the infant study, it was identified that cytomegalovirus (CMV)-specific IFN-γ 78 
responses were associated with T-cell activation and could have contributed to increased risk 79 
of developing TB disease [20]. 80 
The mycobacterial growth inhibition assay (MGIA) has been developed as a measure of 81 
vaccine immunogenicity ex vivo. Following optimisation works in the past few years [21-23], 82 
the assay has gained attention for its potential ability to detect vaccine-mediated inhibition of 83 
growth following BCG vaccination in adults and infats [24-26]. The assay described in the 84 
present study involves direct co-culture of peripheral blood mononuclear cells (PBMCs) with 85 
mycobacteria, and subsequent measurement of mycobacterial growth inhibition as a 86 
functional assessment of vaccine response. Several studies have demonstrated the ability of 87 
the MGIA to detect changes in the innate and adaptive compartment following vaccination 88 
[25, 27-30]. Recently, Joosten and colleagues (2018) found that the capacity to control 89 
mycobacterial growth following recent Mtb exposure or BCG vaccination is associated with 90 
nonclassical monocytes, and this observation is reflective of the trained innate immune 91 
mechanism [26]. In a study by Jensen t al., IFN-γ was associated with reduction of 92 
mycobacterial growth ex vivo following immunisation with a TB vaccine candidate in mice 93 
[31]. However, in that study the source IFN-γ was not found among the investigated vaccine-94 
specific T-cells, suggesting potential contribution from other cell types, such as NK cells. 95 
In this study, we demonstrated the impact of immune cell phenotype, CMV-specific response 96 
and sex on vaccine-specific mycobacterial growth inibition following historical BCG 97 
vaccination in adult healthy volunteers.  98 
 99 
 100 
Materials and Methods 101 
Study participants and ethics statement 102 
We recruited 100 healthy adult participants with (i) no history of BCG vaccination or (ii) a 103 
history of BCG vaccination more than 6 months before study enrolment. Verbal interviews 104 
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were conducted to determine eligibility based on the absence of any major chronic illness, 105 
current medication administration or symptoms of infection. Participants were aged 18 to 80 106 
years with no evidence of exposure or infection with TB. Participants were excluded if they 107 
were suffering from any persistent medical condition or infection. Sample size was calculated 108 
based on the assumption of effect size 0.70, with power 0.8 and significance level 0.05. 109 
Written informed consent was obtained from all participants prior to enrolment in the study. 110 
Individuals were recruited under protocols approved by the LSHTM Observational Research 111 
Ethics Committee (ref 8762 and 10485). All procedurs were conducted in accordance with 112 
the Declaration of Helsinki, as agreed by the World Medical Association General Assembly 113 
(Washington, 2002) and ICH Good Clinical Practice (GCP). 114 
 115 
PBMCs isolation and IFN-γ Enzyme-linked immunospot (ELISpot) assay 116 
Peripheral blood (50ml) was collected and processed within 6 hours. PBMCs isolation and 117 
IFN-γ ELISpot assay were performed as previously described [32]. PBMCs were 118 
cryopreserved in FBS (Labtech International Ltd, Uckfield, UK) containing 10% DMSO 119 
(Sigma-Aldrich) and stored in -80 oC freezer using CoolCell containers (VWR International, 120 
Lutterworth, UK). PBMCs were thawed and an ex vivo IFN-γ ELISpot assay was performed 121 
to assess antigen-specific response. PBMCs were incubated overnight for 18 hours with 20 122 
µg/ml purified protein derivative (PPD) (Oxford Biosystem, Oxfordshire, UK). Positive 123 
control Phytohemagglutinin (PHA) (10 µg/ml, Sigma-Aldrich) and negative control 124 
(medium-only) wells were included for each participant samples. Results are reported as spot 125 
forming cells (SFC) per million PBMCs, calculated by subtracting the mean of the 126 
unstimulated wells from the mean of antigen wells and correcting for the numbers of PBMC 127 
in the wells. Spots were quantified using an automaed plate reader with ELISpot 5.0 128 
software as well as checked visually. 129 
 130 
Ex vivo Mycobacterial Growth Inhibition Assay 131 
The growth inhibition assay was performed using cryop eserved PBMCs of the study 132 
participants, as previously described [32]. In brief, a 2-ml screw-cap tubes containing 3 x 106 133 
PBMCs in 600 ml of medium were rotated at 37oC with ∼100 Colony Forming Units (CFU) 134 
of BCG Pasteur Aeras strain (Rockville, MD, USA) for 4 days. The PBMCs were then lysed 135 
with sterile water, and the lysate transferred to aBactec MGIT supplemented with PANTA 136 
antibiotics and OADC enrichment broth (all from Becton Dickinson, Oxford, UK). The tube 137 
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was placed in a Bactec MGIT 960 and incubated untilgrowth was detected (measured as time 138 
to positivity [TTP]). Use of a standard curve enables conversion of the TTP of a sample tube 139 
into bacterial numbers (log CFU) (Supplementary Fig. S1). All work with cells pre-BCG 140 
infection and involving BCG infected samples was done in Biosafety Level (BSL) 2 141 
laboratory. 142 
 143 
Enzyme-linked immunosorbent assay (ELISA) 144 
MGIA supernatants were analysed to assess cytokine co centrations by ELISA. The levels of 145 
following cytokines were measured: IFN-γ, interleukin (IL)-12p40, IL-6 [BD OptiEIA kits, 146 
Becton Dickinson, UK], tumor necrosis factor alpha (TNF-α), granulocyte-macrophage 147 
colony-stimulating factor (GM-CSF), interferon-gamma-induced protein 10 (IP-10), 148 
granzyme B, IL-32, IL-22 [R&D Systems, Abingdon, UK], IL-10, IL-17 [BioLegend, 149 
London, UK] and perforin [Abcam, Cambridge, UK]. Assays were performed according to 150 
the manufacturers’ instruction. 151 
 152 
Flow cytometric immune phenotyping 153 
PBMC were washed and stained with 1 µl/ml Live Dead Blue Stain (Invitrogen), followed by 154 
staining with the following titrated antibody for the Lymphocyte panel: 2.5 µl CD3-AF700 155 
(clone UCHT1, Ebioscience, Loughborough, UK), 1.25 µl CD4-APC/Cy7 (clone RPA-T4, 156 
BioLegend), 1.25 µl CD8-Superbright645 (clone RPA-T8, Ebioscience), 2.5 µl CD19-FITC 157 
(clone HIB19, BioLegend), 2.5 µl CD56-APC (clone HCD56, BioLegend), 2.5 µl CD16-158 
BV510 (clone 3G8, BioLegend), 5 µl HLA-DR-PE (clone L243, BioLegend), 5 µl LAG3-159 
PE/Cy7 (clone 11C3C65, BioLegend) and 1.25 µl PD1-BV421 (clone EH12.2H7, 160 
BioLegend). For the Monocyte panel, the cells were stained with the following titrated 161 
antibodies: 2.5 µl CD3-AF700 (clone UCHT1, Ebioscience), 2.5 µl CD19-FITC (clone 162 
HIB19, BioLegend), 2.5 µl CD14-BV421 (clone HCD14, BioLegend), 2.5 µl CD16-BV510 163 
(clone 3G8, BioLegend), 1.25 µl CD86-APC/Cy7 (clone IT2.2, BioLegend), 5 µl HLA-DR-164 
PE (clone L243, BioLegend), 5 µl CD206-APC (clone 15-2, BioLegend), 5 µl CD163-165 
BV605 (clone GHI/61, BioLegend), 2.5 µl CD64-APC/Cy7 (clone 10.1, BioLegend) and 5 µl 166 
CD123-BV650 (clone 6H6, BioLegend). Fluorescence minus one (FMO) controls were set 167 
using cells for each antibody and used to guide gatin . Cells were acquired on a BD LSR II 168 
flow cytometer. Data was analysed with FlowJo software version 10.4 (Treestar Inc., USA). 169 
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Results are presented as percentages of cells after ga ing out of dead cells and doublets. 170 
Gating strategies for the lymphocyte and monocyte panels are described in Supplementary 171 
Fig. S2A and S2B. 172 
 173 
Intracellular cytokine staining (ICS) flow cytometry 174 
The ICS flow cytometry was performed as previously described [32]. In brief, PBMCs were 175 
then incubated alone (medium only) as a negative control, with 5 µg/ml Staphylococcus 176 
enterotoxin B (SEB; Sigma, UK) as a positive control, with ∼100 CFU BCG (as per the 177 
MGIA protocol) and with 10 µg/ml CMV peptide pool (5 peptides, 2 µg/ml/peptides, 178 
ANASPEC, Fremont, CA, USA). The CMV peptide pool used is the same as the Fletcher et 179 
al. study [20]. The incubation with BCG was performed for 4 days and the addition of SEB 180 
and CMV was performed on Day 3. Two hours after the addition of SEB and CMV to the 181 
respective tubes, brefeldin A (Sigma, UK) was added to all tubes which were then incubated 182 
for 18 hours at 37oC until Day 4. Data was acquired using an LSRII flow cytometer (BD 183 
Biosciences) and FACSDiva acquisition software (BD iosciences). ICS flow cytometry data 184 
was analysed using FlowJo software version 10.4 (TreeStar Inc., Ashland, OR, USA). 185 
Samples were gated sequentially on singlet, live, CD14-CD19-, CD3+ (lymphoid), CD4+, 186 
CD8+ cells and negative control stimulation tubes were us d to set cytokine gates (see 187 
Supplementary Fig. S3, ICS gating). 188 
 189 
Statistical analysis 190 
To identify statistical significance of ex vivo growth inhibition (log CFU values) and ELISA 191 
responses, students -test were used. Mann-Whitney U Test was performed to identify 192 
significant differences of the ELISpot, cell surface flow cytometry and ICS responses 193 
between groups. Spearman’s correlation coefficient was used to test for correlations between 194 
growth inhibition and immune responses. A multiple comparison correction was included 195 
(Bonferroni), as indicated in each figure legend. Statistical analyses were performed in 196 




Demographics of enrolled participants 201 
 
 8
One hundred participants were enrolled in the study; 37 vaccine-naïve volunteers with no 202 
history of BCG vaccination and 63 volunteers previously-vaccinated with BCG (average time 203 
since vaccination 29.4 years prior to enrolment). Table 1 summarises the characteristics of 204 
the study participants. Almost 70% of the BCG-vaccinated participants were from the UK. 205 
 206 
Assessment of ex vivo growth inhibition and mycobacterial antigen-specific cytokine 207 
responses  208 
The growth inhibition assay was performed to assess impact of historical BCG vaccination on 209 
ex vivo mycobacterial growth control. Using cryopreserved PBMCs, enhanced growth 210 
inhibition in PBMCs from BCG-vaccinated individuals was observed compared to vaccine-211 
naïve individuals (median log CFU 1.680 and 2.027, p<0.0001, Figure 1A). The IFN-γ 212 
ELISpot assay was performed to measure the magnitude of the mycobacteria-specific 213 
response. The secretion of IFN-γ in response to PPD was elevated in samples from vaccin ted 214 
individuals in comparison to unvaccinated individuals (median SFC 109.5 and 48, p<0.0001, 215 
Figure 1B). There was a significant inverse correlation between higher IFN-γ ELISpot 216 
response and lower mycobacterial growth (p=0.022, Spearman r = -0.23, Figure 1C).  217 
Trends for higher production of Th1-type cytokines (IFN-γ, IP-10, TNF-α, IL-12) as well as 218 
GM-CSF were observed in the BCG-vaccinated group compared to the vaccine-naïve group 219 
(Table 2). There was a statistically significant correlation between higher IL-10 production 220 
and higher mycobacterial growth (Spearman r = 0.37, p=0.0003, Table 2). Meanwhile, 221 
historical BCG-vaccination was associated with significantly increased frequency of 222 
mycobacterial antigen specific IL-2+ CD4 T-cells in the BCG-vaccinated group upon 4 days 223 
of stimulation with BCG (p=0.008, Supplementary Figure S4). Similar trends were observed 224 
with the frequencies of IFN-γ+ as well as TNF-α+ CD4 T-cells (Supplementary Figure S4). 225 
There were no significant correlations between the frequencies of BCG-specific CD4 and 226 
CD8 T-cells and mycobacterial growth, although the observed trends suggest that these cells 227 
may contribute to control of growth (Supplementary Table S1).  228 
 229 
Associations between historical BCG vaccination and the frequency of circulating 230 
leukocyte subsets 231 
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Historical BCG vaccination was not associated with frequencies of circulating leukocytes in 232 
T-cell, NK cell and monocyte compartments (Supplementary Table S2). However, significant 233 
correlations were observed between the frequencies of NK cells and enhanced control of 234 
mycobacterial growth ex vivo in the naïve and BCG-vaccinated groups (p<0.05, Spearman’s 235 
correlations, Table 3). In the BCG-vaccinated group, higher frequency of cytokine-producing 236 
NK cells was associated with reduced mycobacterial g owth (Spearman r = -0.41, p=0.015, 237 
Figure 2A). A higher production of perforin was observed from the cells of BCG-vaccinated 238 
participants compared to naïve (p=0.018, Figure 2B). The production of perforin significantly 239 
correlated with enhanced growth inhibition (Spearman r = -0.44, p=0.013, Figure 2C and 240 
Supplementary Table S3), and the association was still ignificant when the correlation was 241 
performed in the BCG-vaccinated group only (Spearman r = -0.36, p=0.037, data not shown). 242 
Correlations with other measured NK cell associated markers (granzyme, IL-32, IL-22) did 243 
not reach significance (Supplementary Table S3).  244 
 245 
Impacts of CMV-specific T-cell response and T-cell activation on ex vivo mycobacterial 246 
growth inhibition  247 
CMV-specific T-cells producing IFN-γ+ and TNF-α+, notably in the CD8 compartment, were 248 
significantly associated with the frequency of T-cells expressing LAG3 and PD1 markers 249 
(p<0.05, Spearman’s correlations, Table 4 and Figure 3 A-D). Historical BCG-vaccination 250 
was not associated with differences in CMV-specific response nor T-cell activation 251 
(Supplementary Table S2 and S4). However, T-cell activ tion was shown to correlate with 252 
higher growth of mycobacteria ex vivo, particularly in the naïve group (Figure 3 and 253 
Supplementary Table S5). LAG3+ CD4 T-cells were significantly associated with growth of 254 
mycobacteria (p=0.047), with a similar trend for LAG3+ CD8 T-cells (p=0.072) (Figure 3 F 255 
and I).  256 
 257 
Impact of sex on ex vivo mycobacterial growth inhibition and cytokine responses, and its  258 
association with immune cell phenotype 259 
In this study, we demonstrated that sex was associated with differences in immune response 260 
following historical BCG vaccination. First, BCG-vaccinated females exhibited a superior 261 
capacity to control mycobacterial growth when compared to males (p=0.029, Figure 4B). In 262 
contrast, males showed a trend towards higher IFN-γ response from PPD-stimulated PBMCs 263 
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as well as higher IP-10 production in the MGIA supernatant, both in naïve and BCG-264 
vaccinated groups (Figure 4 C-F). Supplementary Table S6 summarises the sex comparisons 265 
of all measured cytokines from the MGIA supernatants.  266 
In the BCG-vaccinated group, females had a higher frequency of cytokine-producing NK 267 
cells (p=0.018, Figure 5A). There was also a higher CD4/CD8 ratio in females compared to 268 
males in the naïve group (p=0.028, Figure 5B). Interestingly, there was a higher frequency of 269 
monocytes in males in the BCG-vaccinated group (p=0.049, Figure 5C), with a trend of 270 
higher monocyte-to-lymphocyte (ML) ratio in BCG-vaccinated males compared to females 271 
(p=0.08, Supplementary Table S7). In terms of T-cell activation, BCG-vaccinated females 272 
exhibited a lower frequency of LAG3+ CD8 T-cells (p=0.0297, Figure 5D). While in the 273 
naïve group, females also had lower frequencies of activated CD8 T-cells expressing HLA-274 
DR, LAG3 and PD1 (p<0.05, Supplementary Table S7). The lower frequencies of activated 275 
T-cells in females may be a consequence of lower CMV-specific CD8 T-cells response 276 




The present study reports that mycobacterial growth inhibition ex vivo is enhanced following 281 
historical BCG vaccination in adult healthy volunteers. In this study, the average time since 282 
BCG vaccination was 29.4 years prior to enrolment. Our results are in line with previous 283 
studies such as Fletcher t al. [24] and Prabowo et al. [32] which detected the impact of 284 
historical BCG vaccination after more than 20 years using the same PBMC-based MGIA. 285 
Most vaccinated individuals enrolled in our study are UK participants in which BCG 286 
vaccination is known to be effective [9]. A higher IFN-γ response was also observed in the 287 
BCG-vaccinated group compared to the naïve group using the ELISpot assay, reflecting the 288 
presence of mycobacterial-specific memory cells. Moreover, there was a significant 289 
correlation between IFN-γ response and lower mycobacterial growth. Several published 290 
MGIA studies reported increased IFN-γ production following BCG vaccination [24, 33, 34], 291 
and BCG-specific IFN-γ response measured by ELISpot assay is known to be associated with 292 
reduced TB disease risk following BCG vaccination in infants [18]. The ELISpot assay 293 
measures all cells that secrete IFN-γ in response to antigen stimulation, including NK cells 294 
and γδ T-cells in addition to conventional T-cells. Focusing on the conventional T-cells 295 
response, in our study, we did not observe a significa t association between Th1-type 296 
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cytokine-expressing T-cells and ex vivo mycobacterial growth inhibition. This finding was in 297 
contrast with the study of Smith et al. [25] which showed an association between MGIA 298 
control capacity and the frequency of polyfunctional CD4 T-cells using studying a small 299 
cohort of BCG-vaccinated infants. However, our results were consistent with the finding of 300 
Joosten et al. [26] using the same PBMC-based MGIA, as well as with a study by Kagina et 301 
al. [35] which showed no association between polyfunctio al T-cells and the risk to develop 302 
TB disease following BCG vaccination. 303 
We also observed trends of higher Th1-type cytokines  the MGIA supernatants from BCG-304 
vaccinated participants compared to the naïve. Interes ingly, there was a strong significant 305 
correlation between IL-10 production and reduced control of mycobacterial growth. This 306 
observation replicates earlier findings, in which IL-10 was associated with reduced x vivo 307 
growth inhibition, and was significantly predictive of mycobacterial growth through 308 
inhibition of other pro-inflammatory cytokines [36, 37]. IL-10 is known to have 309 
immunosuppressive activity by inhibiting T-cell proliferation and IFN-γ production, leading 310 
to reduced macrophage activation [38]. The capacity of individuals to produce IL-10 may 311 
need to be considered when assessing TB vaccine effects in clinical trials. 312 
In this study, the frequency of NK cells – in particular cytokine-producing NK cells – is 313 
associated with enhanced x vivo mycobacterial growth inhibition following historical BCG 314 
vaccination. This may account for our correlation between IFN-γ ELISpot response and 315 
control of mycobacterial growth as IFN-γ secreting NK cells will be measured in addition to 316 
CD4 and CD8 positive T-cells. Our results again support a recent finding, in which a greater 317 
frequency of putative cytokine-producing CD16- NK cells was associated with reduced 318 
mycobacterial growth in the multiple regression analysis of MVA85A correlate of risk study 319 
[36, 39]. Cytokine-producing NK cells are the main source of NK-cell derived cytokines such 320 
as IFN-γ, TNF-α and GM-CSF [40], which were modestly increased in the MGIA 321 
supernatants of the BCG-vaccinated group in our study. Initially, cytotoxicity and cytokine-322 
producing functions of NK cells were regarded as two distinct functions with little synergy 323 
between them [40, 41]. However, it was recently shown that IFN-γ and TNF-α could 324 
synergistically enhance NK cell cytotoxicity [42]. In our study, cells obtained from BCG-325 
vaccinated participants produced a higher level of perforin and the secretion of this lytic 326 
granules was associated with enhanced growth inhibition.  327 
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Although considered a component of innate immune system, an emerging body of evidence 328 
has revealed that NK cells can also behave in a memory-like manner following infection or 329 
vaccination [reviewed in [43, 44]]. NK cells isolated from pleural fluid express the memory 330 
marker CD45RO and produce higher amounts of IFN-γ and IL-22 in response to stimulation 331 
with IL-12, IL-15 and BCG when compared with CD45RO- cells [45, 46]. Even though NK 332 
cells do not have antigen receptors generated by genetic rearrangement, they possess 333 
receptors which allow direct antigenic contact, resulting in subsequent cellular activation 334 
[44]. This process will generate antigen-specific NK cells, which lead to enhanced response 335 
following re-exposure with the same stimulus [47, 48]. In addition, work by Kleinnijenhuis et 336 
al. reveals that BCG vaccination promotes augmented secondary responses towards the same 337 
and unrelated stimulus through trained innate immunity mechanism [49]. The growth 338 
inhibition assay has recently been shown to be ableto detect contribution from the trained 339 
innate immune compartment, following Mtb exposure or BCG vaccination, by the role of 340 
nonclassical monocytes [26]. Our present study has s own the additional contribution of NK 341 
cells to ex vivo mycobacterial growth control, and in line with this, recent clinical trials also 342 
reported that immune cells associated with protection from TB disease and after BCG 343 
vaccination were not T-cells, but IFN-γ–producing NK cells [50, 51]. 344 
Furthermore, we have demonstrated that a CMV-specific response may be associated with T-345 
cell activation, in particular in the CD8 compartment, and this activation is correlated with 346 
mycobacterial growth ex vivo. In HIV, T-cell activation has been established as a risk factor 347 
for acquisition of infection as well as progression from infection to disease [52-54]. In TB, 348 
evidence has emerged denoting the role of CMV and T-cell activation on TB disease risk [18, 349 
20], and our study is the first the show such associati n with ex vivo mycobacterial growth. In 350 
this study, we chose to measure CMV-specific T-cell ytokine response with ICS flow 351 
cytometry rather than with serology, as evidence in the literature showed that CMV-antibody 352 
levels do not correlate with the size of the T-cell r sponse against CMV and the ICS method 353 
is more sensitive for detection of CMV-specific cytokine-producing T-cells [55, 56]. 354 
Unfortunately in this study due to a technical limitation, we were unable to perform CMV 355 
serology in our cohort samples. CMV infection is recognised to drive the expansion of 356 
NKG2C+ NK cells [57], which do not respond well to cytokine stimulation discussed above 357 
[58, 59]. Further studies are required to better understand the interplay between CMV-358 
specific response, T-cell activation and NK cells in the context of BCG vaccination.  359 
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Differences in TB disease notification rates between the sexes are well documented and 360 
thought to be a result of biological factors, in addition to social factors [11, 14, 60]. 361 
Therefore, it is of interest that our study demonstrated a higher capacity of BCG-vaccinated 362 
females to control mycobacterial growth ex vivo compared to males. In conjunction to this 363 
data, we found that females had a higher frequency of cytokine-producing NK cells, and 364 
lower frequency of activated T-cells as well CMV-specific response. In addition, females also 365 
had a lower monocyte frequency, with a trend of a lower ML ratio compared to males. 366 
Altogether, these individual-level factors appear to contribute to the enhanced growth 367 
inhibition in females following BCG vaccination. Such sex specific effect has also been 368 
observed with measles and smallpox vaccines, where females are more protected than males 369 
following vaccination [61, 62]. The epidemiological observation that the sex bias in TB does 370 
not arise until puberty has suggested the important role of sex hormones [11]. In general, 371 
testosterone is considered to downregulate the Th1 response, whereas estrogen is believed to 372 
enhance it [14]. Moreover, genetic or epigenetic differences between sex may also play a role 373 
as well in the observed sex-differential protective eff ct [13]. 374 
In summary, we have demonstrated the impact of individual-level factors on ex vivo 375 
mycobacterial growth inhibition in a cohort of healthy, adult volunteers. Our results indicate 376 
that immune cell phenotype, cytomegalovirus-specific response and sex have impacts on 377 
immunity following BCG vaccination. These x vivo observations are reflective of 378 
epidemiological data and published human studies, and such impacts may need to be 379 
considered when testing TB vaccine candidates in trial populations. Importantly, researchers 380 
should consider the impact of sex in clinical vaccine studies, as the impact of sex in 381 
infectious diseases is common but often neglected [63]. The MGIA assay offers an ex vivo 382 
testing platform for assessment of a wide range of candidate TB vaccines, either using BCG 383 
or virulent Mtb as the immune target, with the ability to reflect in er-individual variation 384 
which may be important for vaccine effectiveness. The ex vivo MGIA is therefore an 385 
important additional tool for the TB vaccine community and should continue to be assessed 386 
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Table 1. Characteristics of study participants. 586 
 587 
Characteristic 
Total Participants : 100 
Naïve ( n = 37 ) BCG Vaccinated ( n = 63 ) 
Female [no. (%)] 28 ( 75.7 % ) 42 ( 66.7 % ) 
Median age [yr (range)] 31 
( 23 – 70 ) 
39 
( 24 – 80 ) 
Average time since BCG 
vaccination [yr (range)] 
- 29.4 
( 10 – 58 ) 
Country of Origin 
UK [no. (%)] 
8 ( 21.6 % ) 44 ( 69.8 % ) 
 588 
Table 2. Summary of mean cytokine responses measured with ELISA assays, assessed 589 
from MGIA supernatant samples after 4 days of co-culture. Comparisons were made between 590 
naïve and BCG-vaccinated groups (unpaired t-test), the values indicate mean of concentration 591 
in pg/ml [95% CI]. Correlations were assessed with ex vivo mycobacterial growth among 592 
responders (Spearman’s correlation). A p value <0.05 was considered statistically significant 593 
(in bold), and after a multiple testing correction ly values with p <0.0063 were considered 594 




Comparison Correlation with ex vivo 
mycobacterial growth 
Naïve BCG-vaccinated p-value r p-value 
IFN-γ 12.47 [8.245-16.69] 23.37 [10.8-35.94] 0.1962 -0.027 0.8432 
IP-10 111.7 [55.42-168] 204.5 [112.1-297] 0.1505 0.19 0.1158 
TNF-α 37.97 [2.547-73.4] 97.98 [38.61-157.4] 0.1471 -0.35 0.0558 
IL-12 27.6 [3.033-52.17] 63.61 [20.83-106.4] 0.2299 -0.23 0.3158 
IL-10 52.55 [31.07-74.03] 59.99 [36.56-83.41] 0.6688 0.37*** 0.0003 
GM-CSF 7.729 [-1.688-17.15] 88.54 [26.19-150.9] 0.0512 -0.37 0.1552 
IL-6 356.7 [246.1-467.3] 315 [236.5-393.4] 0.5293 0.071 0.5449 
IL-17 0.00 [0.00-0.00] 0.1596 [0.00-0.4083] 0.3291 -0.13 0.2141 
 597 
Table 3. Correlation of immune cell frequencies in peripheral blood and ex vivo 598 
mycobacterial growth inhibition. Assessment was performed from 16 BCG-naïve and 34 599 
BCG-vaccinated participants. Correlations were performed from a total of 50 participants, as 600 
well as from each naïve and BCG-vaccinated groups respectively (Spearman’s correlation). A 601 
p value <0.05 was considered statistically significant (in bold), and after a multiple testing 602 
correction only values with p <0.0031 were considere  significant (underlined). Note: The 603 
ML ratio was obtained by dividing the percentage of monocytes by the sum of the 604 
percentages of T- and B-cells. The NK cell ratio was obtained by dividing the percentage of 605 




Correlation with ex vivo mycobacterial growth 
All participants Naïve BCG-vaccinated 
r p-value r p-value r p-value 
T-cells -0.068 0.6367 0.29 0.2708 -0.30 0.0866 
   CD4 T-cells -0.041 0.7764 0.17 0.5172 -0.091 0.6080 
   CD8 T-cells 0.24 0.0938 0.36 0.1714 0.093 0.6011 
   CD4/CD8 ratio -0.16 0.2718 -0.20 0.4579 -0.058 0.7448 
NK cells -0.27 0.0593 -0.71** 0.0028 -0.19 0.2833 
   Cytokine NK cell -0.26 0.0702 -0.47 0.0679 -0.41* 0.0147 
   Cytotoxic NK cell -0.25 0.0814 -0.64** 0.0093 -0.19 0.2699 
   NK cell ratio -0.2 0.1602 -0.35 0.1866 -0.087 0.6241 
Monocytes 0.12 0.4244 -0.0088 0.9758 0.13 0.4638 
   ML ratio 0.064 0.6609 -0.044 0.8714 0.083 0.6390 
   M1 monocytes -0.076 0.5993 -0.28 0.2867 -0.031 0.8610 
   M2 monocytes -0.16 0.2784 -0.16 0.5458 -0.12 0.4978 
   M1/M2 ratio 0.059 0.6831 -0.17 0.5283 0.15 0.3939 
   CD64+ monocytes -0.063 0.6659 -0.29 0.2664 0.028 0.8759 
   CD123+ monocytes -0.072 0.6169 -0.27 0.3025 0.015 0.9313 
   Suppressor monocytes 0.21 0.1414 0.31 0.2381 0.089 0.6149 
 607 
Table 4. Correlation of CMV-specific T-cell responses and T-cell activation. Associations 608 
were investigated from 3 different subsets of CMV-specific cytokine+ T-cells producing IFN-609 
γ+, IL-2+ or TNF-α+, respectively. Three markers were used for T-cell activation: HLA-DR, 610 
LAG3 and PD1. A p value <0.05 was considered statistically significant (in bold), and after a 611 
multiple testing correction only values with p <0.083 were considered significant 612 
(underlined) (Spearman’s correlation). n=50 participants, consisted of 16 BCG-naïve and 613 
n=34 BCG-vaccinated participants. *p<0.05, **p<0.01. 614 
CMV-specific 
cytokine+ T-cells 
Correlation with activated T-cells 
HLA-DR + CD4 T-cells LAG3+ CD4 T-cells PD1+ CD4 T-cells 
r  p-value r  p-value r  p-value 
IFN-γ+ CD4 T-cells 0.026 0.8748 -0.004 0.9805 0.20 0.2112 
IL-2+ CD4 T-cells -0.045 0.7823 -0.056 0.7310 -0.0082 0.96 1 
TNF-α+ CD4 T-cells 0.054 0.7401 0.058 0.7239 0.091 0.5757 
  HLA-DR + CD8 T-cells LAG3+ CD8 T-cells PD1+ CD8 T-cells 
IFN-γ+ CD8 T-cells 0.31 0.0552 0.39* 0.0140 0.44** 0.0049 
IL-2+ CD8 T-cells -0.087 0.5917 0.0024 0.9885 -0.15 0.3609 





Figure Legends 617 
 618 
 619 
Figure 1. Growth inhibition and immune responses following historical BCG 620 
vaccination. Assessment was performed from 37 BCG-naïve and 63 BCG-vaccinated 621 
participants. (A) Growth inhibition was compared using BCG input ∼ 100 Colony Forming 622 
Unit (CFU) as immune target (unpaired t-test). Data is presented as total number of log CFUs 623 
per sample, which was determined by use of a standard curve. (B) IFN-γ production from 624 
PBMC following stimulation with PPD was compared (Mann-Whitney test). Numbers above 625 
each group represent median (range). SFC, spot forming cells. (C) The correlation between 626 
ex vivo growth inhibition and PPD-specific IFN-γ response was assessed (Spearman’s 627 
correlation). A p value <0.05 was considered statistically significant. Dots and squares 628 
represent individual data points, and the central lines indicate the median response with inter-629 
quartile range (IQR). ****p<0.0001. 630 
 631 
Figure 2. NK cells correlations. A higher frequency of cytokine-producing NK cells 632 
(CD56bright CD16+/-) correlated with enhanced ex vivo mycobacterial growth inhibition 633 
(Spearman’s correlation) (A). A perforin ELISA was performed from MGIA supernatan s 634 
and the response was compared between vaccination groups (unpaired t-test) (B). The 635 
production of perforin was associated with enhanced ex vivo growth inhibition (Spearman’s) 636 
(C). A p value <0.05 was considered statistically significant. *p<0.05, **p<0.01. 637 
 638 
Figure 3. CMV-specific responses were associated with higher CD8 T-cell activation, 639 
expressing markers LAG3 (A-B) and PD1 (C-D) respectively. Activated CD4 and CD8 T-640 
cells (E-J) were correlated with higher growth of mycobacteria, notably in the naïve groups 641 
(F, I). A p value <0.05 was considered statistically signif cant (Spearman’s correlation). n=50 642 
participants, consisted of 16 BCG-naïve and 34 BCG-vaccinated participants. *p<0.05, 643 
**p<0.01. 644 
 645 
Figure 4. Sex impact on growth inhibition and immune responses following historical 646 
BCG vaccination. Assessment was performed from 37 BCG-naïve (A,C,E) and 63 BCG-647 
vaccinated participants (B,D,F). (A-B) Growth inhibition was compared between sex and 648 
data was presented as total number of log CFUs per sample (unpaired t-test). (C-D) IFN-γ 649 
production from PBMC following stimulation with PPD was compared (Mann-Whitney test). 650 
Numbers above each group represent median (range). SFC, spot forming cells. (E-F) IP-10 651 
was measured from MGIA supernatants using ELISA assay (mean, unpaired t-test). Dots and 652 
squares represent individual data points, and the central lines indicate the median response 653 
with IQR. *p<0.05. 654 
 655 
Figure 5. Comparison by sex of immune cells phenotype (A-C), T-cell activation (D) and 656 
CMV-specific T-cell response (E). Assessment was performed from 16 BCG-naïve and 34 657 
BCG-vaccinated participants. The box plots show the minimum and maximum values (ends 658 
of the whiskers), the median (band near the middle of the box) and interquartile ranges. Blue 659 
and red colour represent males and females, respectively. A p value <0.05 was considered 660 
statistically significant (Mann-Whitney). *p<0.05, **p<0.01, ****p<0.0001. 661 





